Search Results
Mar 26, 2026, 16:05 ET Renibus Therapeutics Announces Participation at the 25th Annual Needham Virtual Healthcare Conference
for the treatment of metabolic acidosis in adults with chronic kidney disease. The Company's second late-stage program, RBT-1, recently completed the PROTECT Phase 3 trial evaluating RBT-1 in patients undergoing cardiac surgery. Results from this trial suggest that further development in risk-enriched
More news about: Renibus Therapeutics
Mar 13, 2026, 10:30 ET Breath Analyzers Market worth $5.63 billion by 2031 | MarketsandMarkets™
https://www.marketsandmarkets.com/requestsampleNew.asp?id=57484012Law enforcement agencies accounted for the largest market share in 2025.Many countries have introduced random breath testing (RBT) programs as a preventive strategy to deter drunk driving. Under these programs, law enforcement officers can stop drivers at random and test their BAC
More news about: MarketsandMarkets
Feb 23, 2026, 10:00 ET Soar Autism Center Announces Free 40-Hour RBT Training To Support ESDM-Focused Learning
Martin. "By aligning RBT training with ESDM principles, we're helping raise the standard of care for children with autism everywhere."The training is available now through Soar's website, with participants receiving a completion certificate verifying fulfillment of the 40-hour RBT training requirement
More news about: Soar Autism Center
Feb 19, 2026, 16:05 ET Renibus Therapeutics Announces Participation at the 36th Annual Oppenheimer Life Sciences Conference
treatment of metabolic acidosis in adults with chronic kidney disease.The Company's second late-stage program, RBT-1, recently completed the PROTECT Phase 3 trial evaluating RBT-1 in patients undergoing cardiac surgery. Results from this trial suggest that further development in risk-enriched patients
More news about: Renibus Therapeutics
Feb 18, 2026, 07:35 ET Knight Therapeutics anuncia la solicitud de autorización regulatoria de NIKTIMVO® (axatilimab) en Brasil
núm. 10 (2023): 1864-1875. doi:10.1200/JCO.22.00958Associação Brasileira de Transplante de Órgãos. (2024). Registro Brasileño de Trasplantes (RBT): Datos numéricos de la donación de órganos y trasplantes realizados por estado e institución en el período: enero/septiembre 2024 (Año XXV, nº 3) [Informe].
More news about: Knight Therapeutics Inc.
Feb 18, 2026, 07:35 ET Knight Therapeutics anuncia a submissão regulatória de NIKTIMVO® (axatilimabe) no Brasil
10 (2023): 1864-1875. doi:10.1200/JCO.22.00958 Associação Brasileira de Transplante de Órgãos. (2024). Registro Brasileiro de Transplantes (RBT): Dados numéricos da doação de órgãos e transplantes realizados por estado e instituição no período: janeiro/setembro 2024 (Ano XXV, nº 3) [Relatório].
More news about: Knight Therapeutics Inc.
Aug 07, 2025, 15:02 ET Back to School, Top of the Class: Florida Charter Schools Ace 2024-25, Beating the State and Boosting Student Success
underserved students." The analysis and 2025 Florida Charter School Report Card, compiled by Dr. Jessica Barr of RBT Data, draws on public data released by the Florida Department of Education on July 7, 2025. The report reinforces how charter
More news about: Florida Charter School Alliance
Aug 04, 2025, 17:36 ET A Knight Therapeutics e a Incyte alteram acordo de fornecimento e distribuição para adicionar Retifanlimabe e Axatilimabe na América Latina
https://site.abto.org.br/wp-content/uploads/2024/11/RBT2024-3t-abto-populacao.pdf.Sobre a Knight Therapeutics Inc. A Knight Therapeutics Inc., com sede em Montreal,
More news about: Knight Therapeutics Inc.
Aug 04, 2025, 17:35 ET Knight Therapeutics e Incyte amplían su acuerdo de suministro y distribución para agregar retifanlimab y axatilimab en Latinoamérica
https://site.abto.org.br/wp-content/uploads/2024/11/RBT2024-3t-abto-populacao.pdf.Acerca de Knight Therapeutics Inc. Knight Therapeutics Inc., con sede en Montreal,
More news about: Knight Therapeutics Inc.
Jun 10, 2025, 08:00 ET Renibus Therapeutics Announces FDA Orphan Drug Designation for Veverimer for the Treatment of Anti-glomerular Basement Membrane Disease (anti-GBM)
Renibus' lead first-in class combination drug therapy is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. RBT-1 has just completed enrollment in a Phase 3 pivotal trial (called
More news about: Renibus Therapeutics
May 05, 2025, 09:00 ET Behavior Frontiers Announces Sale to NexPhase Capital
home for the field's most talented and passionate providers and staff. Its in-house training program, built on PrioraCare, has driven market leading (RBT) pass rates for new hires, significantly exceeding industry averages and showcasing the potential of integrated technology and clinical training.
More news about: Lorient Capital
Apr 25, 2025, 16:05 ET Renibus Therapeutics Announces Poster Presentation on RBT-1 at the 47th Annual Meeting of the Society of Cardiovascular Anesthesiologists (SCA)
poster presentation will be delivered on RBT-1 at the 47th Annual Meeting of the Society of Cardiovascular Anesthesiologists (SCA), taking place April 26-29, 2025 in Montreal. RBT-1 is a single-dose, first-in-class, preconditioning
More news about: Renibus Therapeutics
Apr 24, 2025, 08:00 ET Renibus Therapeutics Announces Completion of Enrollment in PROTECT, a Pivotal Phase 3 Clinical Trial of RBT-1 to Reduce the Risk of Post-Operative Complications After Cardiac Surgery
School of Medicine, Atrium Health Wake Forest Baptist Medical. "I am excited about the potential for RBT-1 to improve patient outcomes and reduce healthcare costs." About RBT-1 RBT-1 is a potent inducer of anti-inflammatory and antioxidant pathways and is currently being evaluated
More news about: Renibus Therapeutics